On September 21, 2020 BioProtect ltd., a private company with a unique bioabsorbable polymer spacer balloon platform, reported the final closing of $25 million of its Series D equity financing from an unnamed strategic investor and Peregrine Ventures (Press release, BioProtect, SEP 21, 2020, View Source [SID1234565459]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These investors are joining the round led by Almeda Ventures and Vincent Tchenguiz, chairman of Consensus Business Group, a prominent private equity investor in Israel and the UK, with the participation of KB Investments of South Korea and Triventures.
Proceeds of the round will finance the ongoing multicenter FDA clinical trial of BioProtect’s lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy, as well as the expansion of the technology platform.
Every year, more than 1.1 million men are diagnosed with prostate cancer worldwide and approximately 400,000 will undergo prostate radiotherapy. Historically prostate radiation therapy was limited by concerns over risk of rectal toxicity following radiotherapy.
The ProSpace balloon spacer helps reduction of radiation therapy risks by pushing the prostate away from adjacent organ at risk, the rectum. Once injected the spacer offers physicians a consistent gap of over 1.5cm, which is visible under trans rectal ultrasound as well as CT. The spacer remains stable during radiation therapy and is gradually absorbed after radiation therapy is completed.
BioProtect’s future pipeline represents a $4 billion opportunity, with additional applications for cervical cancer radiation therapy, pancreas radiation and general surgery. The versatility and physician appeal of a bioabsorbable polymer balloon spacer was further validated last year when a BioProtect spinout for musculoskeletal applications, Orthospace, was acquired by Stryker for a reported $220M.
Gil Rosen, CEO of BioProtect, stated on the round, "This financing will allow the company to complete the pivotal study, gain FDA approval, and accelerate development of the next indication to our platform."